2 results match your criteria: "Canada 2CONRAD Clinical Research Center[Affiliation]"
Combined data of intravaginal prasterone against vulvovaginal atrophy of menopause.
Menopause
November 2017
1Endoceutics Inc., Quebec City, Quebec, Canada 2CONRAD Clinical Research Center, Norfolk, VA.
Objective: To analyze the effects of intravaginal prasterone obtained in the three randomized clinical studies performed in postmenopausal women suffering from moderate to severe (MS) dyspareunia due to vulvovaginal atrophy (VVA).
Methods: In three independent 12-week prospective, randomized, double-blind, and placebo-controlled clinical studies, the effect of daily intravaginal 0.50% (6.
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Menopause
March 2016
1EndoCeutics Inc, Quebec City, Quebec, Canada 2CONRAD Clinical Research Center, Norfolk, VA 3Medical Center for Clinical Research, San Diego, CA 4Clinique Médicale St-Louis (recherche) Inc, Quebec City, Quebec, Canada 5Northern California Research, Sacramento, CA 6Q&T Recherche Sherbrooke, Sherbrooke, Quebec, Canada 7Columbus Center for Women's Health Research, Columbus, OH 8Veristat, Holliston, MA 9StatLog Consulting Inc, Ottawa, Ontario, Canada.
Objective: The aim of this study is to confirm the local beneficial effects of intravaginal dehydroepiandrosterone (DHEA, Prasterone) on moderate to severe dyspareunia or pain at sexual activity, the most frequent symptom of vulvovaginal atrophy due to menopause or genitourinary syndrome of menopause (GSM).
Methods: In a prospective, randomized, double-blind, and placebo-controlled phase III clinical trial, the effect of daily intravaginal 0.50% DHEA (6.